Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-label, International, Multicenter, Interventional Study Exploring the Efficacy of Once-daily Oral Rivaroxaban (BAY 59-7939) for the Treatment of Left Atrial/Left Atrial Appendage Thrombus in Subjects With Nonvalvular Atrial Fibrillation or Atrial Flutter

NCT01839357 is registered in ClinicalTrials.gov with Bayer as lead sponsor.

NCT NCT01839357
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01839357 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-label, International, Multicenter, Interventional Study Exploring the Efficacy of Once-daily Oral Rivaroxaban (BAY 59-7939) for the Treatment of Left Atrial/Left Atrial Appendage Thrombus in Subjects With Nonvalvular Atrial Fibrillation or Atrial Flutter
Lead sponsor
Bayer
Phase
Phase 3
Overall status
Completed
Start date
August 31, 2013
Completion date
December 31, 2014
Enrollment
60 (actual)
Sites
31

Conditions

As the registry lists them; a condition with its own page is linked.

atrial fibrillation